{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:18:17Z","timestamp":1783423097693,"version":"3.54.6"},"reference-count":106,"publisher":"IMR Press","issue":"6","license":[{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br. J. Hosp. Med. (Lond)"],"abstract":"<jats:p>Nasopharyngeal carcinoma is a common Epstein-Barr virus (EBV)-associated malignant tumour of the head and neck region. Accurate prognosis evaluation, risk stratification, and follow-up monitoring are essential for improving patient survival and quality of life. Multimodal positron emission tomography\/computed tomography (PET\/CT) image fusion has shown considerable promise in the diagnosis, staging, response assessment, and prognostic evaluation of nasopharyngeal cancer. This review examines the application of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography (18F-FDG PET\/CT)-derived parameters together with biochemical markers in prognostic models for nasopharyngeal cancer. Biochemical markers, including EBV DNA, lactate dehydrogenase, C-reactive protein, and inflammation-based indices associated with patient prognosis, are summarised. These markers may enhance the accuracy of prognostic assessment and provide critical supplementary information for imaging evaluation. Integrating imaging parameters with biochemical markers is expected to establish a more comprehensive prognostic evaluation system. Multimodal image fusion combined with systematic biochemical indicator monitoring offers novel concepts and techniques for the prognostic evaluation of nasopharyngeal carcinoma (NPC). Future research should focus on standardised PET\/CT acquisition, validated segmentation methods, reliable biochemical assays, and prospective multicentre model validation to improve therapeutic outcomes and survival rates in affected patients.<\/jats:p>","DOI":"10.31083\/bjhm55375","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:55:28Z","timestamp":1783421728000},"source":"Crossref","is-referenced-by-count":0,"title":["Multimodal PET\/CT Image Fusion-Derived Parameters and Biochemical Indices for Prognostic Monitoring in Nasopharyngeal Carcinoma: A Review"],"prefix":"10.31083","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4013-2590","authenticated-orcid":true,"given":"Qidi","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Otolaryngology, Jiaxing University Master Degree Cultivation Base, Zhejiang Chinese Medical University, 314100 Jiaxing, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6075-0195","authenticated-orcid":true,"given":"Lili","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Jiaxing Traditional Chinese Medicine Hospital, 314199 Jiaxing, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0796-9322","authenticated-orcid":true,"given":"Jing","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Jiaxing University Master Degree Cultivation Base, Zhejiang Chinese Medical University, 314100 Jiaxing, Zhejiang, China"},{"name":"Department of Otolaryngology, The First Hospital of Jiaxing, 314000 Jiaxing, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019; 394: 64\u201380.","DOI":"10.1016\/S0140-6736(19)30956-0"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Wong KCW, Hui EP, Lo KW, Lam WKJ, Johnson D, Li L, et al. Nasopharyngeal carcinoma: an evolving paradigm. Nature Reviews. Clinical Oncology. 2021; 18: 679\u2013695.","DOI":"10.1038\/s41571-021-00524-x"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Liu Y, Ye SY, He S, Chi DM, Wang XZ, Wen YF, et al. Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma. Nature Communications. 2024; 15: 7713.","DOI":"10.1038\/s41467-024-52153-4"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Jiang W, Lv JW, Tang LL, Sun Y, Chen YP, Ma J. Enhancing efficacy and reducing toxicity: Therapeutic optimization in locoregionally advanced nasopharyngeal carcinoma. Cell Reports. Medicine. 2024; 5: 101594.","DOI":"10.1016\/j.xcrm.2024.101594"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Wang Z, Fang M, Zhang J, Tang L, Zhong L, Li H, et al. Radiomics and Deep Learning in Nasopharyngeal Carcinoma: A Review. IEEE Reviews in Biomedical Engineering. 2024; 17: 118\u2013135.","DOI":"10.1109\/RBME.2023.3269776"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Li KY, Kwok HM, Pan NY, Cheng LF, Ma KFJ. Pre-treatment and post-treatment nasopharyngeal carcinoma imaging: imaging updates, pearls and pitfalls. Neuroradiology. 2025; 67: 1023\u20131047.","DOI":"10.1007\/s00234-025-03596-z"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. European Journal of Nuclear Medicine and Molecular Imaging. 2015; 42: 328\u2013354.","DOI":"10.1007\/s00259-014-2961-x"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Graham MM, Wahl RL, Hoffman JM, Yap JT, Sunderland JJ, Boellaard R, et al. Summary of the UPICT Protocol for 18F-FDG PET\/CT Imaging in Oncology Clinical Trials. Journal of Nuclear Medicine. 2015; 56: 955\u2013961.","DOI":"10.2967\/jnumed.115.158402"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Lin J, Xie G, Liao G, Wang B, Yan M, Li H, et al. Prognostic value of 18F-FDG-PET\/CT in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Oncotarget. 2017; 8: 33884\u201333896.","DOI":"10.18632\/oncotarget.13934"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Zschaeck S, Li Y, Lin Q, Beck M, Amthauer H, Bauersachs L, et al. Prognostic value of baseline [18F]-fluorodeoxyglucose positron emission tomography parameters MTV, TLG and asphericity in an international multicenter cohort of nasopharyngeal carcinoma patients. PLoS ONE. 2020; 15: e0236841.","DOI":"10.1371\/journal.pone.0236841"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Chang KP, Tsang NM, Liao CT, Hsu CL, Chung MJ, Lo CW, et al. Prognostic significance of 18F-FDG PET parameters and plasma Epstein-Barr virus DNA load in patients with nasopharyngeal carcinoma. Journal of Nuclear Medicine. 2012; 53: 21\u201328.","DOI":"10.2967\/jnumed.111.090696"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Chen WH, Tang LQ, Zhang L, Chen QY, Guo SS, Liu LT, et al. Combining plasma Epstein-Barr virus DNA and nodal maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography improved prognostic stratification to predict distant metastasis for locoregionally advanced nasopharyngeal carcinoma. Oncotarget. 2015; 6: 38296\u201338307.","DOI":"10.18632\/oncotarget.5699"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Lee SW, Nam SY, Im KC, Kim JS, Choi EK, Ahn SD, et al. Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiotherapy and Oncology. 2008; 87: 211\u2013216.","DOI":"10.1016\/j.radonc.2008.01.009"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Chan WKS, Kwong DLW, Yeung DWC, Huang B, Khong PL. Prognostic impact of standardized uptake value of F-18 FDG PET\/CT in nasopharyngeal carcinoma. Clinical Nuclear Medicine. 2011; 36: 1007\u20131011.","DOI":"10.1097\/RLU.0b013e31821a29a4"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Liu WS, Wu MF, Tseng HC, Liu JT, Weng JH, Li YC, et al. The role of pretreatment FDG-PET in nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 2012; 82: 561\u2013566.","DOI":"10.1016\/j.ijrobp.2010.11.055"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Hung TM, Wang HM, Kang CJ, Huang SF, Liao CT, Chan SC, et al. Pretreatment (18)F-FDG PET standardized uptake value of primary tumor and neck lymph nodes as a predictor of distant metastasis for patients with nasopharyngeal carcinoma. Oral Oncology. 2013; 49: 169\u2013174.","DOI":"10.1016\/j.oraloncology.2012.08.011"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Xiao W, Xu A, Han F, Lin X, Lu L, Shen G, et al. Positron emission tomography-computed tomography before treatment is highly prognostic of distant metastasis in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy treatment: a prospective study with long-term follow-up. Oral Oncology. 2015; 51: 363\u2013369.","DOI":"10.1016\/j.oraloncology.2015.01.001"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Xie P, Yue JB, Fu Z, Feng R, Yu JM. Prognostic value of 18F-FDG PET\/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma. Annals of Oncology. 2010; 21: 1078\u20131082.","DOI":"10.1093\/annonc\/mdp430"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Shen T, Tang LQ, Luo DH, Chen QY, Li PJ, Mai DM, et al. Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET\/CT for nasopharyngeal carcinoma patients with recurrence. PLoS ONE. 2015; 10: e0122756.","DOI":"10.1371\/journal.pone.0122756"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Zhang Y, Li WF, Mao YP, Zhou GQ, Peng H, Sun Y, et al. Establishment of an integrated model incorporating standardised uptake value and N-classification for predicting metastasis in nasopharyngeal carcinoma. Oncotarget. 2016; 7: 13612\u201313620.","DOI":"10.18632\/oncotarget.7253"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Chan SC, Hsu CL, Yen TC, Ng SH, Liao CT, Wang HM. The role of 18F-FDG PET\/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma. Oral Oncology. 2013; 49: 71\u201378.","DOI":"10.1016\/j.oraloncology.2012.07.016"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Moon SH, Choi JY, Lee HJ, Son YI, Baek CH, Ahn YC, et al. Prognostic value of volume-based PET\/CT in patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy. Clinical and Experimental Otorhinolaryngology. 2015; 8: 142\u2013148.","DOI":"10.3342\/ceo.2015.8.2.142"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Yoon HI, Kim KH, Lee J, Roh YH, Yun M, Cho BC, et al. The clinical usefulness of 18F-FDG PET to predict oncologic outcomes and PET-based radiotherapeutic considerations in locally advanced nasopharyngeal carcinoma. Cancer Research and Treatment. 2016; 48: 928\u2013941.","DOI":"10.4143\/crt.2015.022"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Yoon YH, Lee SH, Hong SL, Kim SJ, Roh HJ, Cho KS. Prognostic value of metabolic tumor volume as measured by fluorine-18-fluorodeoxyglucose positron emission tomography\/computed tomography in nasopharyngeal carcinoma. International Forum of Allergy & Rhinology. 2014; 4: 845\u2013850.","DOI":"10.1002\/alr.21363"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Yan W, Sun C, Ou X, Hu C. Prognostic value of pre-treatment FDG PET\/CT SUVmax for metastatic lesions in de novo metastatic nasopharyngeal carcinoma following chemotherapy and locoregional radiotherapy. Cancer Imaging. 2023; 23: 21.","DOI":"10.1186\/s40644-023-00536-z"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Sun XS, Liang YJ, Liu SL, Chen QY, Guo SS, Wen YF, et al. Maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography compared with Epstein-Barr virus DNA as prognostic indicators in de novo metastatic nasopharyngeal carcinoma patients. BMC Cancer. 2019; 19: 908.","DOI":"10.1186\/s12885-019-6106-2"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Mo Y, Wei Y, Liang L, Wu T, Li X, Li R, et al. Clinical significance of post-chemoradiotherapy 2-[18F]FDG PET\/CT response in locally advanced nasopharyngeal carcinoma: a real-world study. Oral Oncology. 2025; 161: 107160.","DOI":"10.1016\/j.oraloncology.2024.107160"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Quartuccio N, Sireci F, Pulizzi S, Nicolosi S, D\u2019Oppido D, Ialuna S. Predictive Value of [18F]FDG PET\/CT for Neoadjuvant Chemoradiotherapy Response in Nasopharyngeal Carcinoma. Journal of Clinical Medicine. 2025; 14: 6508.","DOI":"10.3390\/jcm14186508"},{"key":"ref29","unstructured":"Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Research. 1999; 59: 1188\u20131191."},{"key":"ref30","unstructured":"Lo YMD, Chan ATC, Chan LYS, Leung SF, Lam CWK, Huang DP, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Research. 2000; 60: 6878\u20136881."},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. New England Journal of Medicine. 2004; 350: 2461\u20132470.","DOI":"10.1056\/NEJMoa032260"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Leung SF, Zee B, Ma BB, Hui EP, Mo F, Lai M, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. Journal of Clinical Oncology. 2006; 24: 5414\u20135418.","DOI":"10.1200\/JCO.2006.07.7982"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Leung SF, Chan KCA, Ma BB, Hui EP, Mo F, Chow KCK, et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Annals of Oncology. 2014; 25: 1204\u20131208.","DOI":"10.1093\/annonc\/mdu117"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, et al. Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer. The New England Journal of Medicine. 2017; 377: 513\u2013522.","DOI":"10.1056\/NEJMoa1701717"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Chan ATC, Hui EP, Ngan RKC, Tung SY, Cheng ACK, Ng WT, et al. Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. Journal of Clinical Oncology. 2018; 36: 3091\u20133100.","DOI":"10.1200\/JCO.2018.77.7847"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Li WF, Zhang Y, Huang XB, Du XJ, Tang LL, Chen L, et al. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy. Chinese Journal of Cancer. 2017; 36: 87.","DOI":"10.1186\/s40880-017-0256-x"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Li W, Yang C, Lv Z, Li J, Li Z, Yuan X, et al. Integrating pre- and post-treatment Plasma Epstein-Barr Virus DNA levels for better prognostic prediction of Nasopharyngeal Carcinoma. Journal of Cancer. 2021; 12: 2715\u20132722.","DOI":"10.7150\/jca.56397"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Liu Y, Yan W, Qi X, Zhang Y, Wang K, Qu Y, et al. Significance of longitudinal Epstein-Barr virus DNA combined with multipoint tumor response for dynamic risk stratification and treatment adaptation in nasopharyngeal carcinoma. Cancer Letters. 2024; 605: 217276.","DOI":"10.1016\/j.canlet.2024.217276"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Lv J, Xu LX, Li ZX, Lin L, Wu CF, Quan TQ, et al. Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study. Cancer Cell. 2024; 42: 1401\u20131414.e4.","DOI":"10.1016\/j.ccell.2024.07.001"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Qiu SF, Zhang QZ, Wu ZY, Liu MZ, Ding Q, Sun FM, et al. Establishment and validation of circulating cell-free DNA signatures for nasopharyngeal carcinoma detection. eBioMedicine. 2024; 108: 105321.","DOI":"10.1016\/j.ebiom.2024.105321"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Yang S, Zhao K, Ding X, Jiang H, Lu H. Prognostic Significance of Hematological Markers for Patients with Nasopharyngeal Carcinoma: A Meta-analysis. Journal of Cancer. 2019; 10: 2568\u20132577.","DOI":"10.7150\/jca.26770"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Zhang M, Wei S, Su L, Lv W, Hong J. Prognostic significance of pretreated serum lactate dehydrogenase level in nasopharyngeal carcinoma among Chinese population: A meta-analysis. Medicine. 2016; 95: e4494.","DOI":"10.1097\/MD.0000000000004494"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Zhou GQ, Tang LL, Mao YP, Chen L, Li WF, Sun Y, et al. Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma: a predictor of poor prognosis and subsequent liver metastasis. International Journal of Radiation Oncology, Biology, Physics. 2012; 82: e359\u2013e365.","DOI":"10.1016\/j.ijrobp.2011.06.1967"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Fang Y, Xu C, Wu P, Zhang LH, Li DW, Sun JH, et al. Prognostic role of C-reactive protein in patients with nasopharyngeal carcinoma: A meta-analysis and literature review. Medicine. 2017; 96: e8463.","DOI":"10.1097\/MD.0000000000008463"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Chen R, Zhou Y, Yuan Y, Zhang Q, He S, Chen Y, et al. Effect of CRP and Kinetics of CRP in Prognosis of Nasopharyngeal Carcinoma. Frontiers in Oncology. 2019; 9: 89.","DOI":"10.3389\/fonc.2019.00089"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Tang LQ, Hu DP, Chen QY, Zhang L, Lai XP, He Y, et al. Elevated high-sensitivity C-reactive protein levels predict decreased survival for nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era. PLoS ONE. 2015; 10: e0122965.","DOI":"10.1371\/journal.pone.0122965"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Xia WX, Ye YF, Lu X, Wang L, Ke LR, Zhang HB, et al. The impact of baseline serum C-reactive protein and C-reactive protein kinetics on the prognosis of metastatic nasopharyngeal carcinoma patients treated with palliative chemotherapy. PLoS ONE. 2013; 8: e76958.","DOI":"10.1371\/journal.pone.0076958"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Zwanenburg A, Valli\u00e8res M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, et al. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. Radiology. 2020; 295: 328\u2013338.","DOI":"10.1148\/radiol.2020191145"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD Statement. Annals of Internal Medicine. 2015; 162: 55\u201363.","DOI":"10.7326\/M14-0697"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Annals of Internal Medicine. 2015; 162: W1\u2013W73.","DOI":"10.7326\/M14-0698"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies. Annals of Internal Medicine. 2019; 170: 51\u201358.","DOI":"10.7326\/M18-1376"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using \u201coptimal\u201d cutpoints in the evaluation of prognostic factors. Journal of the National Cancer Institute. 1994; 86: 829\u2013835.","DOI":"10.1093\/jnci\/86.11.829"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Medical Decision Making. 2006; 26: 565\u2013574.","DOI":"10.1177\/0272989X06295361"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Pu\u0219ca\u0219 IM, G\u00e2ta A, Roman A, Albu S, G\u00e2ta VA, Irimie A. Integrating Radiomics and Deep-Learning for Prognostic Evaluation in Nasopharyngeal Carcinoma. Medicina. 2025; 61: 1310.","DOI":"10.3390\/medicina61071310"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Zhou J, Wibawa MS, Wang R, Deng Y, Huang H, Luo Z, et al. Multimodal AI-based risk stratification for distant metastasis in nasopharyngeal carcinoma. ESMO Open. 2025; 10: 105809.","DOI":"10.1016\/j.esmoop.2025.105809"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Liu ZQ, Zang SB, OuYang PY, Jing BZ, Zheng CY, Zhao YN, et al. Multimodal prognostic model for de novo metastatic nasopharyngeal carcinoma after first-line immunochemotherapy. Radiotherapy and Oncology. 2025; 210: 111010.","DOI":"10.1016\/j.radonc.2025.111010"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Chen ZH, Han X, Lin L, Lin GY, Li B, Kou J, et al. Harnessing deep learning to optimize induction chemotherapy choices in nasopharyngeal carcinoma. Radiotherapy and Oncology. 2025; 211: 111047.","DOI":"10.1016\/j.radonc.2025.111047"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Li JY, Huang CL, Luo WJ, Zhang Y, Tang LL, Peng H, et al. An integrated model of the gross tumor volume of cervical lymph nodes and pretreatment plasma Epstein-Barr virus DNA predicts survival of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a big-data intelligence platform-based analysis. Therapeutic Advances in Medical Oncology. 2019; 11: 1758835919877729.","DOI":"10.1177\/1758835919877729"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Sharkey AR, Cook GJ. Novel Molecular Imaging Approaches: Towards a Better Estimation of Response in Breast Cancer. British Journal of Hospital Medicine. 2025; 86: 1\u201315.","DOI":"10.12968\/hmed.2024.0959"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Liu T, Xu W, Yan WL, Ye M, Bai YR, Huang G. FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review. Radiotherapy and Oncology. 2007; 85: 327\u2013335.","DOI":"10.1016\/j.radonc.2007.11.002"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Zhou H, Shen G, Zhang W, Cai H, Zhou Y, Li L. 18F-FDG PET\/CT for the Diagnosis of Residual or Recurrent Nasopharyngeal Carcinoma After Radiotherapy: A Metaanalysis. Journal of Nuclear Medicine. 2016; 57: 342\u2013347.","DOI":"10.2967\/jnumed.115.165407"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Shen G, Zhang W, Jia Z, Li J, Wang Q, Deng H. Meta-analysis of diagnostic value of 18F-FDG PET or PET\/CT for detecting lymph node and distant metastases in patients with nasopharyngeal carcinoma. The British Journal of Radiology. 2014; 87: 20140296.","DOI":"10.1259\/bjr.20140296"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Chang MC, Chen JH, Liang JA, Yang KT, Cheng KY, Kao CH. Accuracy of whole-body FDG-PET and FDG-PET\/CT in M staging of nasopharyngeal carcinoma: a systematic review and meta-analysis. European Journal of Radiology. 2013; 82: 366\u2013373.","DOI":"10.1016\/j.ejrad.2012.06.031"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Bossi P, Chan AT, Licitra L, Trama A, Orlandi E, Hui EP, et al. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Annals of Oncology. 2021; 32: 452\u2013465.","DOI":"10.1016\/j.annonc.2020.12.007"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Lee AWM, Lee VHF, Ng WT, Strojan P, Saba NF, Rinaldo A, et al. A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. European Journal of Cancer. 2021; 153: 109\u2013122.","DOI":"10.1016\/j.ejca.2021.05.022"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Lam WKJ, Lo YMD. Plasma Epstein-Barr virus DNA analysis for personalised management of nasopharyngeal carcinoma-current opportunities and challenges. Annals of Nasopharynx Cancer. 2022; 6: 4.","DOI":"10.21037\/anpc-21-11"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Long G, Tang W, Fu X, Li J, Wang Z, Li Y, et al. Pre-treatment serum lactate dehydrogenase predicts distant metastasis and poor survival in nasopharyngeal carcinoma. Journal of Cancer. 2019; 10: 3657\u20133664.","DOI":"10.7150\/jca.32716"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Gao N, Yang RN, Meng Z, Wang WH. The prognostic value of C-reactive protein\/albumin ratio in nasopharyngeal carcinoma: a meta-analysis. Bioscience Reports. 2018; 38: BSR20180686.","DOI":"10.1042\/BSR20180686"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Zeng X, Liu G, Pan Y, Li Y. Prognostic Value of Clinical Biochemistry-Based Indexes in Nasopharyngeal Carcinoma. Frontiers in Oncology. 2020; 10: 146.","DOI":"10.3389\/fonc.2020.00146"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Xiong Y, Shi LL, Zhu LS, Peng G. Prognostic value of pretreatment prognostic nutritional index and lactated dehydrogenase in locally advanced nasopharyngeal carcinoma patients. Annals of Palliative Medicine. 2021; 10: 4122\u20134133.","DOI":"10.21037\/apm-20-2033"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Hsu CL, Chang YS, Li HP. Molecular diagnosis of nasopharyngeal carcinoma: Past and future. Biomedical Journal. 2025; 48: 100748.","DOI":"10.1016\/j.bj.2024.100748"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Zheng XH, Hildesheim A, Jia WH. Advances of biomarkers in nasopharyngeal carcinoma\u2019s early detection. Science Bulletin. 2024; 69: 141\u2013145.","DOI":"10.1016\/j.scib.2023.11.059"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Tang CL, Li XZ, Zhou T, Deng CM, Jiang CT, Zhang YM, et al. EBV DNA methylation profiles and its application in distinguishing nasopharyngeal carcinoma and nasal NK\/T-cell lymphoma. Clinical Epigenetics. 2024; 16: 11.","DOI":"10.1186\/s13148-024-01624-y"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Alfieri S, Roman\u00f2 R, Marceglia S, Sciortino C, Ferrari Bravo W, Zucchini M, et al. Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA study. European Journal of Cancer. 2025; 226: 115625.","DOI":"10.1016\/j.ejca.2025.115625"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Chen X, Xu W, Pan J, Yang H, Li Y, Chen X, et al. m6A methylation profiling as a prognostic marker in nasopharyngeal carcinoma: insights from MeRIP-Seq and RNA-Seq. Frontiers in Immunology. 2024; 15: 1492648.","DOI":"10.3389\/fimmu.2024.1492648"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Xu Z, Sun H, Wang Z, Li J, Gu J. Identifying biomarkers for nasopharyngeal carcinoma diagnosis and chemoradiotherapy response using serum endogenous small molecules profiling. Journal of Pharmaceutical and Biomedical Analysis. 2024; 251: 116428.","DOI":"10.1016\/j.jpba.2024.116428"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Qin G, Liao X, Zhang B, Su Y, Yang H, Xie Y, et al. An individualized immune prognostic signature in nasopharyngeal carcinoma. Oral Oncology. 2024; 157: 106985.","DOI":"10.1016\/j.oraloncology.2024.106985"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Yuan J, Wu M, Qiu L, Xu W, Fei Y, Zhu Y, et al. Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma. Oral Oncology. 2024; 158: 106980.","DOI":"10.1016\/j.oraloncology.2024.106980"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Chen ZK, Wang XQ, Xiao LL, Sun JD, Mao MY, Zhang HB, et al. Construction and application of nasopharyngeal carcinoma-specific big data platform based on electronic health records. American Journal of Otolaryngology. 2024; 45: 104204.","DOI":"10.1016\/j.amjoto.2023.104204"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Jabehdar Maralani P, Kang HT. Middle Neck Involvement: New Layer of Risk Stratification in Nasopharyngeal Carcinoma. Radiology. 2025; 316: e252512.","DOI":"10.1148\/radiol.252512"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Rai P, Lakhani DA, Agarwal A, Bhatt AA. The 9th Version of the AJCC Staging System for Nasopharyngeal Carcinoma: A Guide for Radiologists. AJR. American Journal of Roentgenology. 2025; 225: e2533016.","DOI":"10.2214\/AJR.25.33016"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Chua MLK, Lua JYH, Ng WT, Lee AWM. Management of the neck in nasopharyngeal carcinoma-time for a radical change? Chinese Clinical Oncology. 2023; 12: 8.","DOI":"10.21037\/cco-22-95"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Blanchard P, De Felice F, Chua MLK. Advances in individualization of systemic treatment for locoregionally advanced nasopharyngeal carcinoma: a systematic review. ESMO Open. 2025; 10: 104513.","DOI":"10.1016\/j.esmoop.2025.104513"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Saba NF. Immunotherapeutics in nasopharyngeal carcinoma: a relentless CONTINUUM of success. Lancet. 2024; 403: 2667\u20132669.","DOI":"10.1016\/S0140-6736(24)00810-9"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Sun Y, Kong L. Efficacy and safety of toripalimab in treating nasopharyngeal carcinoma: A meta-analysis. Current Problems in Cancer. 2025; 58: 101238.","DOI":"10.1016\/j.currproblcancer.2025.101238"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Cai T, Lin C, Li Q, Mo J, Zheng J, Zhou J. Efficacy and safety of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma: a systematic review and network meta-analysis. Frontiers in Immunology. 2025; 16: 1485609.","DOI":"10.3389\/fimmu.2025.1485609"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Song Z, Chen L, Zhang Q, Huang Y, Pan H. Optimal combination treatment for Locally Advanced Nasopharyngeal Carcinoma: A systematic review and Bayesian Network Meta-Analysis. American Journal of Otolaryngology. 2025; 46: 104692.","DOI":"10.1016\/j.amjoto.2025.104692"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Guo LF, Hong JG, Wang RJ, Chen GP, Wu SG. Nasopharyngeal carcinoma survival by histology in endemic and non-endemic areas. Annals of Medicine. 2024; 56: 2425066.","DOI":"10.1080\/07853890.2024.2425066"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Ng BHK, Hoe KC, Lim YN, Wong CY, Voon PJ, Tang IP. Nasopharyngeal carcinoma in Sarawak: a 10-year review and update. European Archives of Oto-Rhino-Laryngology. 2024; 281: 6493\u20136498.","DOI":"10.1007\/s00405-024-08955-9"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Chen K, Shi M, Mo S, Liu T, Zhao Y, Zhang L, et al. Clinical features and prognostic factors of nasopharyngeal carcinoma with brain metastases. Oral Oncology. 2024; 151: 106738.","DOI":"10.1016\/j.oraloncology.2024.106738"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Yan L, Lin Y, Lin W, Hong J, Deng M, Chen C, et al. Treatment outcomes in nasopharyngeal carcinoma patients with parotid lymph node metastasis: An 11-year experience at a tertiary cancer center. International Journal of Cancer. 2025; 157: 1218\u20131231.","DOI":"10.1002\/ijc.35470"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Chen K, Cai Y, Jiang L, Tian L. Radiotherapy-Related Quality of Life in Nasopharyngeal Carcinoma Patients: A Systematic Review and Meta-Analysis. ORL. 2024; 86: 200\u2013210.","DOI":"10.1159\/000541124"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Pandrangi VC, Liao JJ, de Almeida JR, El-Sayed IH, Hanna G, Su SY, et al. Current Trends in the Management of Recurrent Nasopharyngeal Carcinoma. Head & Neck. 2025; 47: 2611\u20132621.","DOI":"10.1002\/hed.28219"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Killock D. Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes. Nature Reviews. Clinical Oncology. 2023; 20: 283.","DOI":"10.1038\/s41571-023-00753-2"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"You R, Shen Q, Lin C, Dong K, Liu X, Xu H, et al. Single-cell and spatial transcriptomics reveal mechanisms of radioresistance and immune escape in recurrent nasopharyngeal carcinoma. Nature Genetics. 2025; 57: 1950\u20131965.","DOI":"10.1038\/s41588-025-02253-8"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Huang SY, Gong S, Zhao Y, Ye ML, Li JY, He QM, et al. PJA1-mediated suppression of pyroptosis as a driver of docetaxel resistance in nasopharyngeal carcinoma. Nature Communications. 2024; 15: 5300.","DOI":"10.1038\/s41467-024-49675-2"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"Li QJ, Fang XL, Li YQ, Lin JY, Huang CL, He SW, et al. DCAF7 Acts as A Scaffold to Recruit USP10 for G3BP1 Deubiquitylation and Facilitates Chemoresistance and Metastasis in Nasopharyngeal Carcinoma. Advanced Science. 2024; 11: e2403262.","DOI":"10.1002\/advs.202403262"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Guo S, Xing S, Wu Z, Chen F, Pan X, Li Q, et al. Leucine restriction ameliorates Fusobacterium nucleatum-driven malignant progression and radioresistance in nasopharyngeal carcinoma. Cell Reports. Medicine. 2024; 5: 101753.","DOI":"10.1016\/j.xcrm.2024.101753"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Zhang X, Qian S, Wu P, Yu B, Yin D, Peng X, et al. Tumor-associated macrophage-derived itaconic acid contributes to nasopharyngeal carcinoma progression by promoting immune escape via TET2. Cell Communication and Signaling. 2024; 22: 413.","DOI":"10.1186\/s12964-024-01799-0"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Feng P, Wang Y, Liu N, Chen Y, Hu Y, Huang Z, et al. High expression of PPP1CC promotes NHEJ-mediated DNA repair leading to radioresistance and poor prognosis in nasopharyngeal carcinoma. Cell Death and Differentiation. 2024; 31: 683\u2013696.","DOI":"10.1038\/s41418-024-01287-5"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"Chen KL, Huang SW, Yao JJ, He SW, Gong S, Tan XR, et al. LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein. Drug Resistance Updates. 2024; 76: 101111.","DOI":"10.1016\/j.drup.2024.101111"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"Wu WB, Xia L, Feng ZK, Liang JL, Ding X, Chen SY, et al. Characteristics and treatment of epistaxis in nasopharyngeal carcinoma. Oral Oncology. 2024; 159: 107071.","DOI":"10.1016\/j.oraloncology.2024.107071"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"Cao Y, Li H, Gao Y, Long J, Zheng L, Zhang Q, et al. Esketamine induces apoptosis of nasopharyngeal carcinoma cells through the PERK\/CHOP pathway. Toxicology and Applied Pharmacology. 2024; 483: 116800.","DOI":"10.1016\/j.taap.2023.116800"},{"key":"ref104","doi-asserted-by":"publisher","unstructured":"Lu F, Bai X, Lv Z, Zhang W. Immune archetypes TIME classification system for nasopharyngeal carcinoma: A new direction for precision immunotherapy. Biochimica et Biophysica Acta. Reviews on Cancer. 2025; 1880: 189487.","DOI":"10.1016\/j.bbcan.2025.189487"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"Lin H, Wu Y, Tang F, Lee J, Sun R, Chen K. Deciphering the metabolic-epigenetic-immune crosstalk in Epstein-Barr virus-positive nasopharyngeal carcinoma: mechanisms and novel therapeutic frontiers. International Immunopharmacology. 2025; 164: 115404.","DOI":"10.1016\/j.intimp.2025.115404"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"Ghavidel F, Moalefshahri R, Javid H, Rezagholinejad N, Hashemy SI. The Emerging Role of Heat Shock Proteins in Nasopharyngeal Carcinoma: A Review. Current Medicinal Chemistry. 2025; 32: 2142\u20132155.","DOI":"10.2174\/0929867331666230821110418"}],"container-title":["British Journal of Hospital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/BJHM\/87\/6\/10.31083\/BJHM55375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:55:48Z","timestamp":1783421748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/BJHM\/87\/6\/10.31083\/BJHM55375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":106,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1750-8460(26)03139-0"],"URL":"https:\/\/doi.org\/10.31083\/bjhm55375","relation":{},"ISSN":["1750-8460","1759-7390"],"issn-type":[{"value":"1750-8460","type":"print"},{"value":"1759-7390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,28]]},"article-number":"55375"}}